As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Buy this ebook and get 1 more FREE!
Format PDF ● Pages 444 ● ISBN 9781466579705 ● Publisher CRC Press ● Published 2013 ● Downloadable 6 times ● Currency EUR ● ID 2715426 ● Copy protection Adobe DRM
Requires a DRM capable ebook reader